330
Anti-tumor necrosis factor (anti-TNF) agents
(cont.)
patient education, 28–30
patient preference, 29
pediatric IBD, 42
perioperative risks, 129
pharmacodynamics, 2, 3
pharmacokinetics, 4, 5
population-based study, 42
postoperative complications, 133
pro-inflammatory cytokines, 33
recurrence rate, 223
risks and benefits, 223
safety laboratory monitoring, 26
therapeutic strategies, 44
UC, 13
adalimumab (see Adalimumab)
clinical trials, 14, 26
FDA-approved induction and
maintenance dosing, 19
golimumab (see Golimumab)
indications, 14
infliximab (see Infliximab)
intravenous medications, 27
maintenance dosing schedules, 26
patient preference, 26
placebo-controlled trials, 15
switching therapies, 27, 28
therapy goals, 14
Anti-tumor necrosis factor (anti-TNF) therapy,
143, 152–154, 232–236
ACCENT trial, 142
clinical efficacy, 142
continuation, 142
corticosteroid-sparing effects, 283
discontinuation
disease factors, 153, 154
health economic concerns, 143
IBD management, elderly, 143
infection risk, 143
infusion/local injection reactions, 143
malignancy risk, 143
patient factors, 152, 153
personal preference, 143
treatment factors, 154
disease relapse, 157
dose intensification, 155
growth and bone health, 172–174
induction and maintenance of remission,
283
malignancy, pediatric IBD, 176
mucosal healing, 283
non-infectious and non-malignant
complications
diagnosis and management, 234, 236
infusion reactions, 232, 235
injection site reaction, 232, 235
pathophysiology, 233, 234
risk factors, 232, 233
predictors of relapse, 152
side effects, 176
therapeutic drug monitoring, 154
withdrawal of therapy, 155, 156
Antiviral therapy, 287
Axial arthritis, IBD-associated, 51B
Bayesian network meta-analysis strategy, 70
Biologic Price and Competition Act (BPCI),
262
Biologic therapies
natural history, IBD, 129
pediatric IBD, 177–179
TNF-expressing inflammatory cell
apoptosis, 129
Biologics, 194–202, 315, 319–325
adalimumab, 316
administration, 315–317
antidrug antibody levels, 317
anti IL12/23 agent, 316
bacterial infections
C. difficile-infection, 197
Legionella infection, 196
Listeria infection, 196
nocardia infection, 196
Streptococcal pneumoniae, 197
baseline colonoscopy, 321
certolizumab pegol, 316
clinical studies, 231
contraindications, 315, 317–319
demyelination, 231
discontinuation
adverse effects, 325
disease state and phenotype, 324
external patient factors, 324
patient assessment, 325
patient preference, 324
tolerability, 324
treatment efficacy, 324
vaccinations, 322
withdrawal of anti-TNF therapy, 324
disease complications, 316
drug concentration, 317
drug selection, 315
eczematous eruptions, 231
golimumab, 316
heart failure, 231Index